Drugs & Targets FDA accepts BMS application for Opdivo + Yervoy for liver cancer November 15, 2019Vol.45 No.43
Drugs & Targets Janssen seeks FDA approval for Imbruvica + rituximab for previously untreated patients with CLL November 15, 2019Vol.45 No.43
Drugs & Targets Canada approves Imbruvica combination for CLL indication November 15, 2019Vol.45 No.43
Drugs & Targets UroGen receives rights to Zalifrelimab for intravesical treatment of urinary tract cancers November 15, 2019Vol.45 No.43
Drugs & TargetsFree AACR Project GENIE begins five-year research project with $36M in industry funding November 01, 2019Vol.45 No.41
Drugs & TargetsFree European Commission approves Astellas’ Xospata indication for relapsed or refractory AML November 01, 2019Vol.45 No.41
Drugs & TargetsFree FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers November 01, 2019Vol.45 No.41
Drugs & TargetsFree MD Anderson, Ziopharm Oncology to expand TCR-T Program November 01, 2019Vol.45 No.41
Drugs & Targets FDA approves indication for Zejula in advanced ovarian, fallopian tube, or primary peritoneal cancer October 25, 2019Vol.45 No.40
Drugs & Targets FDA approves test to identify patients eligible for treatment with Zejula in late-line Ovarian Cancer October 25, 2019Vol.45 No.40
